$17.65
Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes
Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
Overview
52-week range
$5.68
$17
100% of range
Avg surprise (last 3)
-5.8%
Avg reaction (last 2)
-0.4%
50% positive
Latest IV / EM
130%
EM ±29.7% · $18 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.75 | $-0.80 | +6.2% | -1.4% | -1.8% | earnings |
| Thu Aug 7, 2025 | Jun/2025 | $-1.07 | $-0.83 | -28.9% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.74 | $-0.78 | +5.1% | — | +0.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.69 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.75 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.86 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.91 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.82 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.71 | -$1.07 | +33.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-54M | — | $-56M | $-76M | $-55M | — | $-49M | $-50M |
| Net income | — | — | $-51M | $-70M | $-49M | — | $-41M | $-42M |
| EPS (diluted) | — | — | — | — | — | — | $-0.69 | $-0.75 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $75M | $88M | $103M | $73M | $77M | $83M | $102M | $115M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $361M | $387M | $342M | $276M | $318M | $415M | $592M | $678M |
| Total assets | $403M | $448M | $484M | $520M | $580M | $622M | $653M | $681M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $37M | $40M | $33M | $28M | $28M | $31M | $25M | $25M |
| Total equity | — | — | $451M | $492M | $552M | $590M | $628M | $656M |